{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:18Z","timestamp":1791612438083,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Italian Ministry of the University","award":["2017L8Z2EM"],"award-info":[{"award-number":["2017L8Z2EM"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40618-020-01334-1","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T09:02:55Z","timestamp":1593248575000},"page":"1779-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center"],"prefix":"10.1007","volume":"43","author":[{"given":"F.","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fierabracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jaccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scartabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Meola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-642X","authenticated-orcid":false,"given":"G.","family":"Ceccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-0822","authenticated-orcid":false,"given":"F.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"1334_CR1","first-page":"909","volume":"14","author":"GA Bray","year":"1990","unstructured":"Bray GA (1990) Obesity: historical development of scientific and cultural ideas. Int J Obes 14:909\u2013926","journal-title":"Int J Obes"},{"key":"1334_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s42255-019-0095-y","volume":"1","author":"JM Friedman","year":"2019","unstructured":"Friedman JM (2019) Leptin and the endocrine control of energy balance. Nat Metab 1:754\u2013764. https:\/\/doi.org\/10.1038\/s42255-019-0095-y","journal-title":"Nat Metab"},{"key":"1334_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1017\/s0029665100000732","volume":"59","author":"FX Pi-Sunyer","year":"2000","unstructured":"Pi-Sunyer FX (2000) Obesity: criteria and classification. Proc Nutr Soc 59:505\u2013509. https:\/\/doi.org\/10.1017\/s0029665100000732","journal-title":"Proc Nutr Soc"},{"key":"1334_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40618-017-0732-9","volume":"41","author":"P Piaggi","year":"2018","unstructured":"Piaggi P, Vinales KL, Basolo A, Santini F, Krakoff J (2018) Obesity and energy expenditure in the etiology of human obesity: spendthrift and thrifty metabolic phenotypes and energy-sensing mechanisms. J Endocrinol Invest 41:83\u201389. https:\/\/doi.org\/10.1007\/s40618-017-0732-9","journal-title":"J Endocrinol Invest"},{"key":"1334_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000492115","volume":"11","author":"E Pineda","year":"2018","unstructured":"Pineda E, Sanchez-Romero LM, Brown M, Jaccard A, Jewell J, Galea G, Webber L, Breda J (2018) Forecasting future trends in obesity across Europe: the value of improving surveillance. Obes Facts 11:360\u2013371. https:\/\/doi.org\/10.1159\/000492115","journal-title":"Obes Facts"},{"key":"1334_CR6","unstructured":"Sbraccia P, Crialesi R, Nicolucci A (2020) 2nd Italian obesity barometer report. Obesity Monitor. https:\/\/viewer.ipaper.io\/sp-servizi-pubblicitari-srl\/obesity-barometer-monitor\/#\/. Accessed 12 May 2020"},{"key":"1334_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mcna.2017.08.006","volume":"102","author":"DH Ryan","year":"2018","unstructured":"Ryan DH, Kahan S (2018) Guideline recommendations for obesity management. Med Clin North Am 102:49\u201363. https:\/\/doi.org\/10.1016\/j.mcna.2017.08.006","journal-title":"Med Clin North Am"},{"key":"1334_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40519-016-0279-3","volume":"21","author":"F Santini","year":"2016","unstructured":"Santini F, Busetto L, Cresci B, Sbraccia P (2016) SIO management algorithm for patients with overweight or obesity: consensus statement of the Italian Society for Obesity (SIO). Eat Weight Disord 21:305\u2013307. https:\/\/doi.org\/10.1007\/s40519-016-0279-3","journal-title":"Eat Weight Disord"},{"key":"1334_CR9","unstructured":"Agenzia italiana del farmaco (2020) Saxenda allegato 1 riassunto delle caratteristiche del prodotto.https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_000085_044018_RCP.pdf&retry=0&sys=m0b1l3 Accessed 12 May 2020."},{"key":"1334_CR10","unstructured":"Sbraccia P, Muratori F, Santini F, Busetto L, Caretto A, Caregaro Negrin L, Paolini B (2017) Standard italiani per la cura dell\u2019obesit\u00e0 SIO ADI 2016\u20132017. https:\/\/www.sio-obesita.org\/wp-content\/uploads\/2017\/09\/STANDARD-OBESITA-SIO-ADI.pdf. Accessed 12 May 2020."},{"key":"1334_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","volume":"45","author":"H Agers\u00f8","year":"2002","unstructured":"Agers\u00f8 H, Jensen LB, Elbr\u00f8nd B, Rolan P, Zdravkovic M (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195\u2013202. https:\/\/doi.org\/10.1007\/s00125-001-0719-z","journal-title":"Diabetologia"},{"key":"1334_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.2337\/diabetes.50.11.2530","volume":"50","author":"PJ Larsen","year":"2001","unstructured":"Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530\u20132539. https:\/\/doi.org\/10.2337\/diabetes.50.11.2530","journal-title":"Diabetes"},{"key":"1334_CR13","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, Hecksher-S\u00f8rensen J, Cowley MA, Dalb\u00f8ge LS, Hansen G, Grove KL, Pyke C, Raun K, Sch\u00e4ffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124:4473\u20134488. https:\/\/doi.org\/10.1172\/JCI75276","journal-title":"J Clin Invest"},{"key":"1334_CR14","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022-1807 Study Group (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606\u20131616. https:\/\/doi.org\/10.1016\/S0140-6736(09)61375-1","journal-title":"Lancet"},{"key":"1334_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, R\u00f6ssner S, Savolainen MJ, Van Gaal L, NN8022-1807 Investigators (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36:843\u2013854. https:\/\/doi.org\/10.1038\/ijo.2011.158","journal-title":"Int J Obes (Lond)"},{"key":"1334_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante-Ortiz R, Jensen CB, Wilding JP, SCALE Obesity, and Prediabetes NN8022-1839 Study Group (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"N Engl J Med."},{"key":"1334_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, Andreasen AH, Jensen CB, DeFronzo RA, NN8022-1922 Study Group (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314:687\u2013699. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"key":"1334_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes 40:1310\u20131319. https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int J Obes"},{"key":"1334_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L, NN8022-1923 Investigators (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 37:1441\u20131451. https:\/\/doi.org\/10.1038\/ijo.2013.120","journal-title":"Int J Obes"},{"key":"1334_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/dom.12639","volume":"18","author":"JPH Wilding","year":"2016","unstructured":"Wilding JPH, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW (2016) Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab 18:491\u2013499. https:\/\/doi.org\/10.1111\/dom.12639","journal-title":"Diabetes Obes Metab"},{"key":"1334_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","volume":"20","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, the Satiety, and Clinical Adiposity\u2013Liraglutide Evidence in individuals with, and without diabetes (SCALE) study groups (2018) Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab 20:734\u2013739. https:\/\/doi.org\/10.1111\/dom.13125","journal-title":"Diabetes Obes Metab"},{"key":"1334_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D (2020) Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity 28:529\u2013536. https:\/\/doi.org\/10.1002\/oby.22726","journal-title":"Obesity"},{"key":"1334_CR23","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O (2020) Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. https:\/\/doi.org\/10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"key":"1334_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080-2018","author":"S Harari","year":"2018","unstructured":"Harari S (2018) Randomised controlled trials and real-life studies: two answers for one question. Eur Respir Rev. https:\/\/doi.org\/10.1183\/16000617.0080-2018","journal-title":"Eur Respir Rev"},{"key":"1334_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","volume":"27","author":"S Saturni","year":"2014","unstructured":"Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, Santus PA, Morandi l, Papi A (2014) Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther 27:129\u2013138. https:\/\/doi.org\/10.1016\/j.pupt.2014.01.005","journal-title":"Pulm Pharmacol Ther"},{"key":"1334_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/oby.22462","volume":"27","author":"S Wharton","year":"2019","unstructured":"Wharton S, Liu A, Pakseresht A, N\u00f8rtoft E, Haase CL, Mancini J, Power GS, Vanderlelie S, Christensen RAG (2019) Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity 27:917\u2013924. https:\/\/doi.org\/10.1002\/oby.22462","journal-title":"Obesity"},{"key":"1334_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4158\/EP-2019-0169","volume":"26","author":"C Maccora","year":"2020","unstructured":"Maccora C, Ciuoli C, Goracci A, Benenati N, Formichi C, Pilli T, Verdino V, Mnutr ON, Bufano A, Tirone A, Voglino C, Fagiolini A, Castagna MG (2020) One month weight loss predicts the efficacy of liraglutide in obese patients: data from a single center. Endocr Pract 26:235\u2013240. https:\/\/doi.org\/10.4158\/EP-2019-0169","journal-title":"Endocr Pract"},{"key":"1334_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13399","author":"JJ Gorgojo-Mart\u00ednez","year":"2019","unstructured":"Gorgojo-Mart\u00ednez JJ, Basagoiti-Carre\u00f1o B, Sanz-Velasco A, Serrano-Moreno C, Almod\u00f3var-Ruiz F (2019) Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR study. Int J Clin Pract. https:\/\/doi.org\/10.1111\/ijcp.13399","journal-title":"Int J Clin Pract"},{"key":"1334_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1159\/000478099","volume":"10","author":"C le Roux","year":"2017","unstructured":"le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X (2017) Comparison of efficacy and safety of liraglutide 3.0 mg in individuals with BMI above and below 35 kg\/m2: a post-hoc analysis. Obes Facts 10:531\u2013544. https:\/\/doi.org\/10.1159\/000478099","journal-title":"Obes Facts"},{"key":"1334_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40618-015-0385-5","volume":"38","author":"M Rigato","year":"2015","unstructured":"Rigato M, Avogaro A, Fadini GP (2015) Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. J Endocrinol Invest 38:1357\u20131363. https:\/\/doi.org\/10.1007\/s40618-015-0385-5","journal-title":"J Endocrinol Invest"},{"key":"1334_CR31","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/oby.21629","volume":"24","author":"K Fujioka","year":"2016","unstructured":"Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, Skj\u00f8th TV, Bj\u00f8rn Jensen C, P H Wilding J (2016) Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical marker. Obesity 24:2278\u20132288. https:\/\/doi.org\/10.1002\/oby.21629","journal-title":"Obesity"},{"key":"1334_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-017-0912-4","volume":"19","author":"JB Cohen","year":"2017","unstructured":"Cohen JB (2017) Hypertension in obesity and the impact of weight loss. Curr Cardiol Rep 19:98. https:\/\/doi.org\/10.1007\/s11886-017-0912-4","journal-title":"Curr Cardiol Rep"},{"key":"1334_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11906-019-0915-1","volume":"21","author":"JB Cohen","year":"2019","unstructured":"Cohen JB, Gadde KM (2019) Weight loss medications in the treatment of obesity and hypertension. Curr Hypertens Rep 21:16. https:\/\/doi.org\/10.1007\/s11906-019-0915-1","journal-title":"Curr Hypertens Rep"},{"key":"1334_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/oby.22359","volume":"27","author":"TA Wadden","year":"2019","unstructured":"Wadden TA, Walsh O, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, Leonard S, Mugler K, Bakizada Z, Tronieri JS (2019) Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity 27:75\u201386. https:\/\/doi.org\/10.1002\/oby.22359","journal-title":"Obesity"},{"key":"1334_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.diabet.2017.12.007","volume":"44","author":"E Capristo","year":"2017","unstructured":"Capristo E, Panunzi S, De Gaetano A, Raffaelli M, Guidone C, Iaconelli A, L'Abbate L, Birkenfeld AL, Bellantone R, Borstein SR, Mingrone G (2017) Intensive lifestyle modifications with or without liraglutide 3.0 mg vs sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study. Diabetes Metab 44:235\u2013242. https:\/\/doi.org\/10.1016\/j.diabet.2017.12.007","journal-title":"Diabetes Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01334-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T23:12:22Z","timestamp":1624749142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01334-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01334-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.F. has received travel funds from the following companies involved with lipodystrophy, obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk, Aegerion, Amryt Pharmaceuticals.P.F has received travel funds from the following companies involved with obesity and\/or diabetes treatments: Novo Nordisk, Bruno Farmaceutici, LJ Pharma. G.S. has received fees for sponsor seminar and travel funds from the following companies involved with obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk, Penta. R.J. has received travel funds from the following companies involved with obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk, Bioitalia, Nestl\u00e8, Kalibra. J.V. has received travel funds from the following companies involved with obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk, Kalibra, GlaxoSmithKline. G.S. has received travel funds from the following company involved with obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk. A.M. has received travel funds from the following company involved with obesity and\/or diabetes treatments: Novo Nordisk. S.M. has received travel funds from the following companies involved with lipodystrophy, obesity and\/or diabetes treatments<b>:<\/b> Novo Nordisk, Aegerion, Amryt Pharmaceuticals.G.C. has received fees for consulting, and\/or received travel funds from the following companies that are involved with lipodystrophy, obesity and\/or diabetes treatments: AstraZeneca, Aegerion, Novonordisk,\u00a0Amryt Pharmaceuticals and Rhythm Pharmaceuticals. F.S. has worked as a consultant, participated in studies and\/or received travel funds from the following companies that are involved with lipodystrophy, obesity and\/or diabetes treatments: AstraZeneca, Aegerion, Amryt Pharmaceuticals, Bruno Farmaceutici, Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Local Ethical Committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients gave a general consent to the use of anonimysed data for research purpose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}